Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
22.61
+1.36 (6.40%)
At close: Mar 9, 2026, 4:00 PM EDT
22.30
-0.31 (-1.37%)
After-hours: Mar 9, 2026, 4:51 PM EDT
Ultragenyx Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 673 | 560 | 434 | 363.33 | 351.41 | |
| Revenue Growth (YoY) | 20.18% | 29.03% | 19.45% | 3.39% | 29.66% | |
| Cost of Revenue | 859 | 775 | 693 | 734.11 | 513.16 | |
| Gross Profit | -186 | -215 | -259 | -370.78 | -161.76 | |
| Selling, General & Admin | 349 | 321 | 310 | 278.14 | 219.98 | |
| Operating Expenses | 349 | 321 | 310 | 278.14 | 219.98 | |
| Operating Income | -535 | -536 | -569 | -648.92 | -381.74 | |
| Interest Expense | -62 | -63 | -66 | -43.02 | -29.42 | |
| Interest & Investment Income | 25 | 37 | 27 | 11.07 | 1.93 | |
| Other Non Operating Income (Expenses) | 1 | -5 | -1 | -1.57 | -1.69 | |
| EBT Excluding Unusual Items | -571 | -567 | -609 | -682.43 | -410.92 | |
| Gain (Loss) on Sale of Investments | - | - | - | -19.3 | -42.06 | |
| Pretax Income | -571 | -567 | -609 | -701.73 | -452.98 | |
| Income Tax Expense | 4 | 2 | -2 | 5.7 | 1.04 | |
| Net Income | -575 | -569 | -607 | -707.42 | -454.03 | |
| Net Income to Common | -575 | -569 | -607 | -707.42 | -454.03 | |
| Shares Outstanding (Basic) | 99 | 91 | 74 | 70 | 68 | |
| Shares Outstanding (Diluted) | 99 | 91 | 74 | 70 | 68 | |
| Shares Change (YoY) | 8.95% | 23.13% | 5.13% | 3.13% | 11.42% | |
| EPS (Basic) | -5.83 | -6.29 | -8.26 | -10.12 | -6.70 | |
| EPS (Diluted) | -5.83 | -6.29 | -8.26 | -10.12 | -6.70 | |
| Free Cash Flow | -472 | -421 | -519 | -496.59 | -411.79 | |
| Free Cash Flow Per Share | -4.79 | -4.65 | -7.06 | -7.10 | -6.07 | |
| Gross Margin | -27.64% | -38.39% | -59.68% | -102.05% | -46.03% | |
| Operating Margin | -79.50% | -95.71% | -131.11% | -178.60% | -108.63% | |
| Profit Margin | -85.44% | -101.61% | -139.86% | -194.70% | -129.20% | |
| Free Cash Flow Margin | -70.13% | -75.18% | -119.59% | -136.68% | -117.18% | |
| EBITDA | -500 | -500 | -543 | -630.7 | -368.5 | |
| EBITDA Margin | -74.29% | -89.29% | -125.11% | -173.59% | -104.86% | |
| D&A For EBITDA | 35 | 36 | 26 | 18.22 | 13.24 | |
| EBIT | -535 | -536 | -569 | -648.92 | -381.74 | |
| EBIT Margin | -79.50% | -95.71% | -131.11% | -178.60% | -108.63% | |
| Revenue as Reported | 673 | 560 | 434 | 363.33 | 351.41 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.